Partners HealthCare is now Mass General Brigham. Soon you’ll see this name across our system—including the Partners Clinical Trials Office. Please bear with us as we transition this website to our new name. Thank you.
Facilitates, Supports, and Aims to Expand the Conduct of Clinical Trials at Partners HealthCare Institutions
Top experts from the Brigham presented outcomes from some of the most-anticipated clinical trials in cardiology at the American College of Cardiology’s 70th Annual Scientific Session (ACC.21) which took place virtually May 15-17. In four late-breaking clinical trial presentations, Brigham cardiologists shared their latest findings on strategies to prevent future cardiovascular events in at-risk patient populations, results of a randomized clinical trial of a statin drug among patients critically ill with COVID-19, and more.
Results of a study co-authored by MGH Institute of Health Professions researcher Teresa Kimberley, PhD, PT, have the potential to improve the lives of patients who have had a stroke with resulting arm weakness. The study reports that patients who incorporated vagus nerve stimulation during physical or occupational therapy showed 2 to 3 times the improvement in arm and hand function compared to those who received intense rehabilitation with sham stimulation.
For patients who have experienced certain common types of stroke, a small chip inserted under the skin may help physicians predict their likelihood of experiencing a second stroke, and therefore their likelihood of benefiting from preventive therapy. The findings come from a recent clinical trial led by investigators at Massachusetts General Hospital (MGH) and Northwestern University Feinberg School of Medicine.
The HEALEY ALS Platform Trial, the first ever platform trial for ALS, continues to gain momentum just months after launching in 2020, passing the 50% participant enrollment milestone for the first 3 regimens.